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Abstract 
The most diverged region of the primary amino acid sequence between cardiac (cTnC) and fast skeletal troponin C is the N-terminal ten amino 
acids. We report here that major changes in the primary sequence of this region in cTnC had a minimal effect on the abiity of the mutant proteins 
to recover maximal activity in TnC-extracted cardiac and fast skeletal muscle myofibrils. However, deletion of the N-terminal nine amino acids 
resulted in a 60% decrease in maximal Ca”-dependent ATPase activity with only a small change in the pCa, of activation. Deletion of the N-terminal 
peptide did not appear to appreciably affect the Ca*‘-binding properties of cTnC, but it did alter the interaction with hydrophobic fluorescent probes. 
Thus, the presence but not the sequence, of the N-terminal extension is important for the maximal activity of cTnC. The N-terminal helix may function 
in a relatively non-specific manner to prevent unfavorable interactions between domains in cTnC or between cTnC and other troponin subunits. 
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1. Introductioll 
The N-terminal peptide of troponin C (TnC), detined 
as those amino acids that are N-terminal to helix A, is 
the most diverged region between the cardiac (cTnC) and 
skeletal (sTnC) isoforms [1,2]. Calmodulin (CaM) shares 
a high degree of structural similarity with TnC [3-6] and 
can functionally substitute for cTnC and sTnC in the 
corresponding muscle types in vitro [7,8], yet it lacks and 
N-terminal peptide. These comparisons uggest hat the 
N-terminal peptide of TnC is not essential for activity, 
but that it might confer isoform-specific functional dif- 
ferences to cardiac and skeletal TnC. 
In the study reported here, we have tested the func- 
tional significance of the N-terminal peptide in cTnC by 
substitution and deletion mutagenesis followed by func- 
tional characterization in cardiac and fast skeletal myofi- 
brils. The data demonstrate that the presence but not the 
primary sequence of the N-terminal peptide in cTnC is 
important for function. 
2. Materials and methods 
The construction of expression plasmids for the recombinant pro- 
teins cTnC3 and cTnCN1 was described previously [9]. Expression 
plasmids for cTnCN3 and cTnC(m were prepared by replacing the 
BamHI-HincII restriction fragment from the plasmid pMC6B with 
various synthetic double-stranded DNA fragments. This resulted in 
either deletion or modification of the first 11 codons of the chicken 
cTnC cDNA. The modified cDNAs were isolated as NcoI-Hind111 
restriction fragments and used to replace the corresponding fragment 
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in the expression plasmid pTnCPL3 which encodes normal cTnC [9]. 
The expression plasmid for cTnC(FLAG) was constructe.d using PCR. 
All proteins were isolated using the chromatographic procedure de- 
scribed previously [9] with slight modifications. Western blots of 
cTnC(PLAG) proteins were performed according to standard proce- 
dures using a kit obtained from IBI/Kodak. Purified proteins were 
diluted with 0.05 M Tris, pH 7.4,0.15 M NaCl and 0.1 ml was applied 
to Nytran nitrocellulose membranes. The membranes were allowed to 
dry, saturated with excess casein protein and exposed to the Ml or M2 
FLAG antibody (IBIIKodak) followed by an anti-rabbit antibody con- 
jugated to horseradish peroxidase. 
Myofibril ATPase assays were performed as described previously 
[lo]. Equilibrium dialysis for the determination of Ca” binding capac- 
ity of the various proteins was performed using microdialysis chambers 
(BRL) in a buffer containing 50 mM MOPS, pH 7.0, 150 mM KCl, 
1 mM dithiothreitol and sutlicient CaC12 to achieve pCa 4.5. Ca*‘-de- 
pendent Tyr and bis-l,l’-bi(4-anilino)naphthalene-5,5’-disulfonic acid 
(bis-ANS from Molecular Probes) fluorescence were performed as de- 
scribed previously [10,111. Protein solutions for all fluorescence xperi- 
ments contained 50 mM MOPS, pH 7.0,150 mM KCl, 0.5 mM EGTA. 
Protein concentrations in all fluorescence experiments were 0.27 mg/ml. 
The final concentration of total CaC12 needed to achieve the desired free 
Ca*+ concentration in the myofibril and fluorescence assays was deter- 
mined using the multiple equilibrium computer programs of Fabiato 
[12]. Apparent binding constants at pH 7.0 and 23°C for all metal 
ligands were calculated using these computer programs. The apparent 
binding constant for EGTA was 2.53 x 106. The concentration of con- 
taminating Ca*’ in the buffers was about 5 x 10e6 M as determined 
using a Ca”-sensitive electrode (Orion) and Ca*%GTA standards. 
3. Results 
3.1. N-Terminal mutants 
The primary sequences of proteins with modifications 
in the N-terminus are shown in Fig. 1A. Expression plas- 
mids for cTnCN1 and cTnCN3 were generated in a pre- 
vious study [9]. In cTnCN1, the first 11 amino acids of 
native cTnC were replaced by the first 12 amino acids 
from helix A of vertebrate CaM. The primary sequence 
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A. Comparison of N-terminal Amino Acid Sequences 
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Fig. 1. Recombinant proteins. (A) The N-terminal ammo acids of cTnC 
and sTnC are compared to the recombinant proteins used in this study. 
The numbering system is relative to tissue-derived cTnC which retains 
the N-terminal Met residue. The presence or absence of the N-terminal 
Met residue in the recombinant proteins was confirmed by amino acid 
sequencing or by antibody cross-reactivity for cTnC(FLAG). Dots 
indicate residues that are the same as in cTnC. Dashes indicate deleted 
residues. The sequence for sTnC is from the human and rabbit proteins 
[21]. (B) Purified proteins were diluted with 0.05 M Tris, pH 7.4, 0.15 
M NaCl such that the indicated quantities of purified protein in a 
volume of 0.1 ml were applied to Nytran nitrocellulose membranes. The 
membranes were then allowed to dry and were exposed to the M2 
FLAG antibody (IBIKodak) followed by an anti-rabbit antibody 
horseradish peroxidase antibody. 
of the N-terminus of cTnCN3 most closely resembles 
normal recombinant cTnC3. cTnC(FLAG) and CBM- 
IIA(FLAG), which has an inactive site II, were gener- 
ated to more rigorously test the requirement for a 
specific N-terminal primary sequence in cTnC and to 
provide a sensitive pitope tag on cTnC for other studies. 
In these constructs the first eight amino acids of the 
normal cTnC were replaced with the highly charged se- 
quence MDYKDDDDK, which specifies the FLAG ep- 
itope (IBUKodak) and an enterokinase cleavage site. 
Fig. 1B shows that as little as 10 ng of purified cTnC 
proteins with the FLAG epitope can be detected by a 
commercially available M2 monoclonal antibody. The 
FLAG proteins do not cross-react with the Ml antibody 
(data not shown) which will only recognize the FLAG 
epitope if the initiator Met is absent. 
Figure 2A shows the maximal levels of ATPase activ- 
ity of TnC-extracted fast skeletal and cardiac muscle 
myofibrils that were reconstituted with cTnC3 or the 
various N-terminal mutants. cTnC@N) was able to re- 
cover only about 40% of the activity recovered by cTnC3 
in both cardiac and fast skeletal muscle myofibrils. All 
other mutants, even cTnC(FLAG), recovered levels of 
ATPase activity similar to, or slightly greater than, the 
153 
activity recovered by cTnC3. The lowered activity of 
cTnC(m does not appear to be due to a less efficient 
incorporation of the protein into the myofibrils since 
concentrations of cTnC(&l of up to 0.15 mg/ml did not 
increase the recovered activity (data not shown). Fig. 2B 
shows that all the N-terminal mutants, even cTnC@N), 
exhibited similar Ca’+-dependent activation characteris- 
tics. The relative pCa, values appear to correlate with 
the relative severity of the mutations. cTnC3 and 
cTnCN3, which differ by only 4 amino acids, have iden- 
tical pCa, values of 5.7, while cTnC(dN) and 
cTnC(FLAG) have slightly lower pCa,, values of 5.5. 
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Fig. 2. Fast skeletal and cardiac myofibril ATPase activities of mutant 
proteins with N-terminal peptide modifications. (A) Myofibril extracts 
of endogenous TnC were reconstituted with no activator, cTnC3, 
cTnCN1, cTnCN3, cTnC(FLAG) or cTnC(m. Ca’+-dependent activ- 
ity is de8ned as the difference in specific activity at pCa 3.6 and 8.0. 
Activity is expressed as the percent of the maximal Ca”-dependent 
activity observed for cTnC3 (about 100 ma01 Pi/min/mg myofibril pro- 
tein in skeletal myofibrils and 12 nmol PJmin/mg myofibril protein in 
cardiac). (B). ATPase activity of myofibrils reconstituted with cTnC3, 
cTnCN1, cTnCN3, cTnC(FLAG) or cTnC(AV) was measured in the 
presence of increasing amounts of Ca”. The data are expressed as the 
percent of the maximal Ca”dependent activity for each cTnC deriva- 
tive. The data was fitted by least squares minimization to the following 
form of the Hill equation, A/A,, = l/(1 + 10n(logCaW 1ogCa)) where 
A is Ca*‘-dependent activity at a given log Ca”, A, is the maximal 
activity, n is the Hill coefficient and log Ca,, is the log of the Ca2+ 
concentration at which the activity is half maximal. Ca2’dependent 
activity is defined as the difference in specific activity at the indicated 
pCa and pCa 8.0. 
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Fig. 3. Caz’-binding capacity of cTnC and its modified derivatives. 
Equilibrium dialysis was performed as described in section 2. CaCl, was 
added to achieve pCa 4.5. Protein concentrations were l-2 m&l. The 
data represent the mean + SD. of duplicate determinations. 
Based on the functional characteristics hown in Fig. 
2, cTnC(m and cTnC(FLAG) were selected for bio- 
chemical characterization. Fig. 3 shows the Ca*‘-binding 
capacity of cTnC(dN) and cTnC(FLAG) determined by 
equilibrium dialysis at a free Ca*’ concentration of 
3.16 x lo-’ M (pCa 4.5). Both proteins bound 3 mol Ca*’ 
per mol protein. The control proteins cTnC3, CBM-III/ 
IVA and CBM-II/III/WA bound 3,1 and 0 mol Ca*’ per 
mol protein as predicted from previously studies [10,131. 
cTnC3, cTnC(FLAG) and cTnC(&) were titrated 
with Ca*+ while monitoring changes in intrinsic Tyr fluo- 
rescence or changes in fluorescence from the soluble 
probe bis-ANS which binds to hydrophobic surfaces on 
proteins. Fig. 4A, shows the effect of increasing concen- 
trations of Ca*’ on fluorescence from bis-ANS in the 
presence of cTnC3, cTnC(FLAG) and cTnC(dN). The 
initial fluorescence, in arbitrary units, at pCa 8.5 was 
370, 240 and 480 for cTnC3, cTnC(FLAG) and 
cTnC(dN), respectively. Titration of both cTnC3 and 
cTnC(FLAG) with Ca*’ caused bis-ANS fluorescence 
transitions that had pCa,o values of 7.0 and 5.3 (see 
Table l), which correspond to the high and low affiity 
sites in cTnC [14]. Steady-state fluorescence continues to 
increase at pCa values greater than 4.0. This phenome- 
non, which has been observed previously with cTnC la- 
beled with 2-(4’-iodoacetarnido)anilino)naphthalene-6- 
sulfonic acid [9,15], may be due to non-specific binding 
of Ca*’ to clusters of acidic amino acids. Titration of 
cTnC(dN) with Ca*’ resulted in a bis-ANS fluorescence 
decrease that had a pCa,, of 7.09, and a subsequent 
gradual increase in fluorescence from pCa 6.0 to 3.0. 
Similar to our previous results [lo], we were unable to 
reproducibly detect a change in Tyr fluorescence from 
cTnC3 in response to Ca*’ binding to the low affinity site 
(see Fig. 4B). This was also true for cTnC(FLAG) which 
is missing Tyr’ but has a Tyr residue in the FLAG epi- 
tope. Both the absolute increase in Tyr fluorescence and 
the pCa,, values were essentially identical for cTnC3 and 
cTnC(FLAG), and corresponded to Ca*+ binding to high 
affinity sites. Titration of cTnC(m with Ca*’ resulted 
in an increase in Tyr fluorescence with a pCa,, that was 
similar to that observed with bis-ANS and slightly 
greater than the pCa,, values for the high atity sites 
in cTnC3 and cTnC(FLAG). 
4. Discussion 
In this study we have attempted to evaluate the func- 
tional significance of the N-terminal helix in cTnC. Our 
primary conclusion is that the presence but not the pri- 
mary sequence of the N-terminal peptide in cTnC is 
essential for function. Even cTnC(FLAG) and cTnCN1, 
in which the first 12 amino acids differ greatly from those 
of cTnC3, show very little functional difference from 
cTnC3 in the myofibril ATPase assays. Only when the 
















Fig. 4. Ca”-dependent bis-ANS and tyrosine fluorescence. (A) Steady- 
state fluorescence from bis-ANS fluorescence at increasing concentra- 
tions of free Ca” in the presence of the indicated proteins. (B) The effect 
of increasing free Ca2+ concentrations on the intrinsic ‘l@ fluorescence 
from the indicated proteins. 
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in maximal ATPase activity. This conclusion is contra- 
dictory to that reached by Gulati et al. [16]. The basis for 
these divergent conclusions may reside in differences in 
experimental design. For the current study, we chose to 
modify only the N-terminal peptide, within the context 
of normal cTnC and without modifications to other re- 
gions of the primary sequence. Gulati et al. chose to use 
chimeric cardiac/skeletal recombinants in which the pri- 
mary sequence was mostly derived from sTnC. Specifi- 
cally, the Ca*’ binding domain I of sTnC was replaced 
with the corresponding region of cTnC to generate a 
chimera with domain I of cTnC and domains II, III and 
IV from sTnC. The activity of this chimera was de- 
creased substantially when it was further modified by 
replacing the first 10 amino acids with the corresponding 
amino acids from sTnC. The relevance of this data to the 
function of normal cTnC must be extrapolated cau- 
tiously since the data was obtained using a chimeric pro- 
tein that derives less than 20% of its primary sequence 
from cTnC and in which normal interactions between 
Ca*‘-binding loops I and II, which are different in cTnC 
vs. sTnC [17,18], may not occur. It is possible that the 
observations of Gulati et al. will apply to sTnC but not 
cTnC. 
Several explanations may account for the lowered ac- 
tivity of cTnC(dN). The simplest is that deletion of the 
N-terminus induces undesirable structural perturbations 
in cTnC. This possibility cannot be excluded without 
extensive biophysical characterization of cTnC(dN). 
However, if deletion of the N-terminal peptide caused 
improper protein folding, then it is likely that the Ca*+- 
binding properties of the low afhnity site II would be 
greatly affected. Deletion of the N-terminal helix altered 
the interaction of cTnC(dN) with bis-ANS such that no 
clear change in fluorescence was observed upon Ca*+ 
binding to the low affinity site. However, direct determi- 
nation of Ca*+ binding by equilibrium dialysis showed 
that cTnC(dN) binds three mol Ca*+ per mol protein at 
pCa 4.5. Although we cannot exclude the possibility that 
deletion of the N-terminal helix causes inactivation of 
site II and activation of site I, it is more likely that sites 
II, III and IV in cTnC(dN) are saturated with Ca*+ at 
pCa 4.5. Moreover, the pCa,, for activation of myofibril 
ATPase by cTnC(m was identical to cTnC(FLAG) and 
only slightly different from cTnC3. If cTnC(dN) did not 
bind Ca*+ at site II, then it would be functionally inactive 
as we have shown previously for cTnC [9]. Thus, deletion 
of the N-terminal helix does not appear to destabilize the 
structure of site II to the extent that it has greatly differ- 
ent Ca*‘-binding properties. 
A second possibility is that removal of the N-terminal 
peptide prevents specific interactions between this region 
and other regions in cTnC, or other thin filament pro- 
teins that are necessary for efficient transmission of the 
Ca*+ signal. This mechanism would be inconsistent with 
the maximal activities of cTnCN1 and cTnC(FLAG), 
since specific interactions would be expected to be dis- 
rupted by such severe mutations. 
A third possibility is that the N-terminal peptide in- 
teracts relatively non-specifically with other regions 
in cTnC or other troponin subunits. Deletion of the 
N-terminus would prevent this and possibly allow other, 
functionally deleterious interactions to occur. Altered 
interactions within cTnC are suggested by Ca*‘-depend- 
ent changes in bis-ANS and Tyr fluorescence. Table 1 
shows that cTnC3, cTnC(FLAG) and cTnC(m showed 
fluorescence transitions with pCasO values that were con- 
sistent with the binding constants for high affinity sites 
III and IV in cTnC as determined by equilibrium dialysis 
[14]. The pCa,, for the high afiity sites in cTnC(dN) 
was slightly greater than the corresponding pCa,, values 
of cTnC3 and cTnC(FLAG). This increase in the appar- 
ent Ca’+-binding amnity is consistent with the increased 
affinity of sites III and IV seen for recombinant C-termi- 
nal fragments of cTnC [lo] and sTnC [19]. This suggests 
that there is an interaction between the N- and C-termi- 
nal domains in the free form of cTnC which involves, at 
least in part, the N-terminal peptide. 
The effect of deletion of the N-terminal peptide on 
fluorescence from bis-ANS suggests that a hydrophobic 
surface is exposed in cTnC(dN). Analysis of a model for 
the predicted tertiary structure of cTnC [20] shows that 
deletion of the first 10 amino acids would cause a signif- 
icant increase in the exposure of Va179 to solvent. In 
CaM, which does not have an N-terminal extension, 
there is a polar Thr residue at the position corresponding 
to Va179 in cTnC. A reasonable hypothesis is that expo- 
sure of the hydrophobic Val residue compromises the 
function of cTnC. To test this we engineered both cTnC 
and cTnC(m) to covert Va179 to Thr. This modification 
resulted in only a slight increase in the Ca*+-dependent 
activity of both cTnC3 and cTnC(dN) (data not shown). 
It is possible that exposure of other residues by them- 
selves, or in synergy, cause the marked decrease in activ- 
ity of cTnC@N) relative to wild-type cTnC. 
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